Medical Access in Rwanda

Currently classified as a strictly controlled substance under Rwanda's narcotics and psychotropic substance regime, with no authorized medical use outside of approved clinical research. [1]Rwanda Narcotics Law (ICNL summary) [2]Rwandan Ministerial Order referencing controlled substances lists

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. [1]Rwanda Narcotics Law (ICNL summary)

Esketamine (branded products such as SPRAVATO) does not appear in publicly available Rwandan regulatory announcements as an approved registered intranasal product; there is no publicly documented national reimbursement or routine public-sector program for esketamine in Rwanda. Rwanda's Ministry of Health determines national drug/psychotropic listings and controls under national narcotics/psychotropic laws, and ministerial orders set the lists of controlled substances and categories. [1]J&J SPRAVATO U.S. approval announcement [2]Rwanda Narcotics Law (ICNL summary)

Practical context in Rwanda: while esketamine products are commercially available in some high‑income countries, Rwanda's current published health-sector activity around rapid-acting NMDA‑modulators centers on ketamine delivered within hospital settings (see Ketamine entry). There are no public sources indicating registration of esketamine with Rwanda's regulatory apparatus or inclusion in national insurance/reimbursement schemes as of the searches informing this report. [3]King Faisal Hospital announcement

Ketamine is legally used in Rwanda in medical settings (anesthetic and, increasingly, psychiatry/psychiatric clinics) and has been introduced as a psychiatric treatment in at least one tertiary/private hospital clinic. King Faisal Hospital in Kigali publicly announced the launch of a ketamine psychiatric clinic providing ketamine infusions for severe depression, trauma-related conditions and treatment‑resistant cases; the Ministry of Health has signaled interest in expanding access. [1]King Faisal Hospital announcement [2]New Times / AllAfrica reporting quoting Rwanda State Minister for Health

Regulatory and reimbursement context: Rwanda's national narcotics/psychotropic legal framework authorizes the Minister of Health to list and regulate narcotics and psychotropic drugs and to set controls and permitted medical uses; ketamine as an established anesthetic is within the medical system's remit under those regulations. However, publicly available documentation does not show a national, government‑funded reimbursement policy (Mutuelle de Santé or other public insurance) that specifically covers ketamine for psychiatric indications. The current operational model appears to be hospital‑based provision (private/tertiary), often implemented through partnerships and clinician training, rather than a standardized, nationally reimbursed mental‑health therapy program. [3]Rwanda Narcotics Law (ICNL summary) [2]New Times / AllAfrica reporting

Clinical indications and practice nuances: available reporting indicates ketamine is being used for severe depression, suicidal ideation and PTSD in patients who have not responded to conventional antidepressant treatments—consistent with international off‑label psychiatric practice—but this in‑country rollout is recent, centered on specific hospital services, and accompanied by external clinical partnerships for training and supervision. There is no publicly available national guidance (ministerial protocol) describing standardized eligibility criteria, dosing protocols, required monitoring or coverage criteria for insurance reimbursement for psychiatric ketamine as of the searches conducted for this report. [1]King Faisal Hospital announcement

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Rwanda's law and ministerial orders govern lists of psychotropic substances and criminalize unauthorized possession, manufacture and distribution. [1]Rwanda Narcotics Law (ICNL summary)

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. [1]Rwanda Narcotics Law (ICNL summary)

There is no evidence of authorized medical frameworks for ibogaine in Rwanda; most jurisdictions treat ibogaine either as a controlled psychotropic or leave it in a legal gray zone without medical authorization — in Rwanda, national narcotics/psychotropic law gives the Minister of Health authority to list and control such substances and there is no public registry showing medical approval for ibogaine. Therefore: Currently classified under the national drug scheduling regime with no authorized medical use outside of approved clinical research or explicit ministerial authorization. [1]Rwanda Narcotics Law (ICNL summary) [2]Survey of international ibogaine legal approaches — contextual source

Currently classified as a strictly controlled substance under Rwanda's narcotics and psychotropic substance regime (ayahuasca contains DMT and related regulated compounds), with no authorized medical use outside of approved clinical research. Public enforcement and prosecutions related to controlled substances are active under Rwanda's penal code and ministerial orders. [1]Rwanda Narcotics Law (ICNL summary) [2]Rwanda Police reporting on controlled‑substance enforcement (illustrative of enforcement activity)

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. As with other classical psychedelics, mescaline/peyote would fall under the Minister of Health's regulatory tables and Rwanda's narcotics statutes for unauthorized manufacture, possession and distribution. [1]Rwanda Narcotics Law (ICNL summary)

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Designer phenethylamines such as the 2C family are encompassed by Rwanda's drug control framework and criminal provisions for unauthorized activity. [1]Rwanda Narcotics Law (ICNL summary)